Here's some of what is coming soon to NeurologyLive® this week.
Commentary|Articles|August 27, 2026
RiMS 2026: Recovery vs Compensation in MS Rehabilitation
Author(s)IJMSC staff
The 31st Annual Rehabilitation in Multiple Sclerosis Conference took up a question DMTs do not answer: when should treatment aim to restore lost function, and when should it aim to work around it?
Advertisement
Advertisement
Disease-modifying therapy (DMT) has changed the trajectory of multiple sclerosis (MS), but it has not resolved what happens to function that is already lost for people with relapsing MS or to people with progressive disease when DMT effects thin out. That gap is where rehabilitation research operates, and it was the subject of the 31st Annual Rehabilitation in Multiple Sclerosis (RiMS) Conference, held June 11-13, 2026, in Prague, Czech Republic.
Related to this article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.
Advertisement
Advertisement